Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04928599 · ClinicalTrials.gov registry record
Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States
A clinical trial of Acute Lymphoblastic Leukemia, sponsored by Children's Oncology Group.
- Active
- Registry status
- 100
- Enrollment target
- 20
- Study locations
NCT04928599 is a study of Acute Lymphoblastic Leukemia that is active but no longer recruiting, run by Children's Oncology Group. The registered enrollment target is 100 participants, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT04928599, a study of Acute Lymphoblastic Leukemia, is active but no longer recruiting, sponsored by Children's Oncology Group.
- ACTIVE NOT RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 20
- Study locations
Study Summary
The overall goals of this study are to measure parents' financial distress (worry or anxiety about money) during their child's/adolescent's treatment for acute lymphoblastic leukemia and whether it changes over time, and to learn what factors are associated with changes in financial distress. Information gathered from this study will inform future intervention studies that may mitigate financial distress for parents of children/adolescents being treated for acute lymphoblastic leukemia.
Conditions Studied
Interventions
- OTHER Survey Administration
- OTHER Electronic Health Record Review
- OTHER Interview
Study Locations (20)
Florida
- Broward Health Medical Center - Fort Lauderdale
- Golisano Children's Hospital of Southwest Florida - Fort Myers
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital - Hollywood
- Nemours Children's Clinic-Jacksonville - Jacksonville
- Nemours Children's Hospital - Orlando
- Sacred Heart Hospital - Pensacola
- Tampa General Hospital - Tampa
- Saint Joseph's Hospital/Children's Hospital-Tampa - Tampa
Louisiana
- Children's Hospital New Orleans - New Orleans
- Ochsner Medical Center Jefferson - New Orleans
Michigan
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital - Grand Rapids
- Bronson Methodist Hospital - Kalamazoo
California
- Kaiser Permanente-Oakland - Oakland
Delaware
- Alfred I duPont Hospital for Children - Wilmington
Georgia
- Augusta University Medical Center - Augusta
Hawaii
- Kapiolani Medical Center for Women and Children - Honolulu
Iowa
- Blank Children's Hospital - Des Moines
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-03-14 |
| Est. Completion | 2028-03-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04928599
The ClinicalTrials.gov registry entry for NCT04928599 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 381-participant average among 131 other Acute Lymphoblastic Leukemia trials with a reported enrollment target (74% lower). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Survey Administration is the first listed.
NCT04928599 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, Louisiana, Michigan.
Frequently Asked Questions
What is clinical trial NCT04928599 about?
NCT04928599 is a clinical study titled "Financial Distress During Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States". The overall goals of this study are to measure parents' financial distress (worry or anxiety about money) during their child's/adolescent's treatment for acute lymphoblastic leukemia and whether it changes over time, and to learn what factors are associated with changes in financial distress. Inform...
What is the current status of trial NCT04928599?
This trial is currently active not recruiting. The enrollment target is 100 participants. The study started on 2022-03-14. Estimated completion is 2028-03-31.
What conditions does trial NCT04928599 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT04928599?
The interventions under investigation include: Survey Administration (OTHER), Electronic Health Record Review (OTHER), Interview (OTHER).
Who is sponsoring clinical trial NCT04928599?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04928599 being conducted?
This trial has 20 study locations across California, Delaware, Florida, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
RECRUITING
-
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RECRUITING · Phase 1
-
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
RECRUITING · Phase 1
-
UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1
RECRUITING · Phase 1
-
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RECRUITING · Phase 1
-
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.